Abstract
Self-expandable metallic stents for the palliation of malignant dysphagia: a single center experience
Highlights
Self-expandable metallic stents (SEMS) for the palliation of unresectable esophageal cancer (EC) is standard of care
Late adverse events (AE) occurred in n=11 patients: death (n=6) unrelated to stent placement, globus sensation /recurrent dysphagia / food impaction (n=5), and stent migration (n=1)
We report the incidence of early and late adverse events, need for repeat stenting, and patient survival
Summary
Self-expandable metallic stents (SEMS) for the palliation of unresectable esophageal cancer (EC) is standard of care. We evaluated the technical success, clinical outcomes, and safety of endoscopic SEMS placement in patients with unresectable EC. The incidence of esophageal cancer continues to increase in the United States, and is currently the fastest rising incident cancer [1]. An estimated 17,990 new cases of esophageal cancer were expected to be diagnosed in 2013, with 15,210 esophageal cancer-related deaths [2]. Worldwide an estimated 482,300 new esophageal cancer cases were diagnosed and 406,800 cancer related deaths occurred in 2008 [3]. Society estimates that 16,980 new cases of esophageal cancer (men 13,570, women 3,410). Will be diagnosed in the United States in 2015 and. We identified all patients who were referred for malignant related esophageal stricture between
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
